Supplementary Figure 2 shows that for all the conditions examined, the viability of LNCaP after 48 h was 99 ± 2% (Panel A) and an identical result was obtained for PC3 cell line (100 ± 1.5%) (Panel B). The viability of the CD45+ population was also not significantly affected by the different treatments in the presence of LNCaP or PC3 cancer cells (Supplementary Panels C, D respectively) or in their absence (Panel E) although there was a small drop to 93% in the LNCaP-PBMC co-cultures and drop to 95% in the PC3-PBMC co-cultures with the 1 μg/ml ADU-S100 and IL-15 combination. Here, IL15 is linked to cancer.